Viracta Therapeutics, Inc. Stock Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 2.33M 3.19M | Capitalization | 32.53M 44.45M |
---|---|---|---|---|---|
Net income 2024 * | -62M -84.72M | Net income 2025 * | -86M -118M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 13.9 x |
P/E ratio 2024 * |
-0.71
x | P/E ratio 2025 * |
-0.74
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.08% |
Latest transcript on Viracta Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 62 | 22-09-18 |
Melody Burcar
DFI | Director of Finance/CFO | 41 | 22-08-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 07-09-30 |
Thomas Darcy
BRD | Director/Board Member | 74 | 21-01-31 |
Barry Simon
BRD | Director/Board Member | 69 | 21-03-02 |
1st Jan change | Capi. | |
---|---|---|
+1.56% | 42.75B | |
+47.70% | 41.61B | |
+12.01% | 41.34B | |
-8.83% | 26.59B | |
+6.99% | 25.49B | |
-23.27% | 18.12B | |
+30.13% | 12.24B | |
-2.39% | 11.76B | |
+8.29% | 11B |